CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 77% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 77% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Daily summary: European stock rally fades despite vaccine optimism

19:16 23 November 2020

• Oxford AstraZeneca COVID-19 vaccine has up to 90% efficacy
• US tops 12 million coronavirus cases
• US plans first COVID-19 vaccinations by mid-December

European stocks erased earlier gains and finished trading near the flatline, as investors digested weak PMI data which showed that the Eurozone private sector shrank more than expected in November, as several member states implemented more restrictions in order to contain the spread of the coronavirus. Meanwhile Oxford and AstraZeneca showed their coronavirus vaccine has two different dosing regimes, one produced 90% effectiveness and the other 62%. Vaccine could be easily transported at normal refrigerator temperatures. Also no hospitalizations or severe cases of the disease were reported in those receiving the treatment. However company’s shares dropped over 3.0% as some investors perceived the efficacy data as disappointing compared with rivals. Meanwhile, Prime Minister Boris Johnson announced that lockdown will end on December 2nd and the UK will move to a 4 Tier system. On the Brexit front, Sky News reported that Brexit deal is 95% agreed on but some differences remain  regarding fisheries, governance and competition.

Start investing today or test a free demo

Open account Try demo Download mobile app Download mobile app

The Dow Jones and the S&P 500 started the week on a positive note while the Nasdaq is swinging between gains and losses as hopes of a COVID-19 vaccine and upbeat PMI data lifted market sentiment. US Food and Drug Administration issued emergency approval for Regeneron coronavirus treatment. Also, vaccinations against Covid-19 in the US will “hopefully” start in less than three weeks, said Moncef Slaoui, head of the government’s Operation Warp Speed. According to media reports, UK may approve Pfizer coronavirus vaccine this week. Meanwhile total number of cases surpassed 12 million over the weekend and more than 83K people were hospitalized on Sunday, the 13th straight day the country has broken its hospitalization record. Today's PMI data showed US business activity in November expanded at the fastest rate in more than five years, topping even the most optimistic analysts' estimates.

US crude futures are trading 1.3% higher while the international benchmark Brent contract rose more than 2.0% an prospects that the distribution of Covid-19 vaccines will enable a thorough recovery in oil demand next year. Meanwhile, Houthi rebels based in Yemen fired a missile that struck an oil distribution center operated by the Saudi Aramco oil company in Saudi Arabia’s Red Sea city of Jeddah. Elsewhere, gold futures fell 1.7% while silver futures dropped 2.3% as investors turned to riskier assets following vaccine news and strong business activity data from the US.

Silver – bears managed to break below the lower limit of the triangle pattern and if the current sentiment prevails then the downward move may accelerate towards the support at $22.15. The nearest resistance lies at $25.00 level. Source: xStation5

This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.

Back
Xtb logo

Join over 1 Million investors from around the world

We use cookies

By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

This group contains cookies that are necessary for our websites to work. They take part in functionalities like language preferences, traffic distribution or keeping user session. They cannot be disabled.

Cookie name
Description
SERVERID
userBranchSymbol cc 2 March 2024
adobe_unique_id cc 1 March 2025
test_cookie cc 1 March 2024
SESSID cc 9 September 2022
__hssc cc 1 March 2024
__cf_bm cc 1 March 2024
intercom-id-iojaybix cc 26 November 2024
intercom-session-iojaybix cc 8 March 2024

We use tools that let us analyze the usage of our page. Such data lets us improve the user experience of our web service.

Cookie name
Description
_gid cc 9 September 2022
_gat_UA-22576382-1 cc 8 September 2022
_gat_UA-121192761-1 cc 8 September 2022
_ga_CBPL72L2EC cc 1 March 2026
_ga cc 1 March 2026
AnalyticsSyncHistory cc 8 October 2022
af_id cc 31 March 2025
afUserId cc 1 March 2026
af_id cc 1 March 2026
AF_SYNC cc 8 March 2024
__hstc cc 28 August 2024
__hssrc

This group of cookies is used to show you ads of topics that you are interested in. It also lets us monitor our marketing activities, it helps to measure the performance of our ads.

Cookie name
Description
MUID cc 26 March 2025
_omappvp cc 11 February 2035
_omappvs cc 1 March 2024
_uetsid cc 2 March 2024
_uetvid cc 26 March 2025
_fbp cc 30 May 2024
fr cc 7 December 2022
muc_ads cc 7 September 2024
lang
_ttp cc 26 March 2025
_tt_enable_cookie cc 26 March 2025
_ttp cc 26 March 2025
hubspotutk cc 28 August 2024

Cookies from this group store your preferences you gave while using the site, so that they will already be here when you visit the page after some time.

Cookie name
Description
personalization_id cc 7 September 2024
UserMatchHistory cc 8 October 2022
bcookie cc 8 September 2023
lidc cc 9 September 2022
lang
bscookie cc 8 September 2023
li_gc cc 7 March 2023

This page uses cookies. Cookies are files stored in your browser and are used by most websites to help personalise your web experience. For more information see our Privacy Policy You can manage cookies by clicking "Settings". If you agree to our use of cookies, click "Accept all".

Change region and language
Country of residence
Language